Publication: Los genéricos: sostén coyuntural o estructural del S.N.S
Loading...
Official URL
Full text at PDC
Publication Date
2015-06
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
En los últimos años, se han producido en España cambios en el patrón de utilización de los medicamentos, pasando del uso de los llamados medicamentos de marca a los fármacos genéricos o por principio activo. En el presente trabajo analizaremos desde el punto de vista regulatorio la práctica de la PPA en España y describiremos este patrón de utilización desde el año 2004 al 2014., observando como el consumo de estos fármacos se ha incrementado de manera progresiva, a la par que se producía un descenso del uso de los medicamentos de prescripción, llegando a una cuota de mercado que si en el año 2004 era del 12%, en el 2014 había ascendido a una cifra muy superior, 46,5%. Comprobaremos como han contribuido a fomentar su disponibilidad y utilización la publicación de Leyes y Decretos-ley ,en especial el Real Decreto ley 9/2011, que dictados por las autoridades sanitarias en aras de disminuir el gasto sanitario y hacer sostenible el sistema nacional de salud ,indirectamente han llevado a que el consumo de medicamentos genéricos y aquellos que han perdido la patente se halla incrementado, al mismo tiempo que la factura en medicamentos ha reducido su peso dentro del SNS, observándose un importante descenso en el 2010 por la incorporación de las medidas dirigidas especialmente a la política de precios y descuentos.
In the last few years there has been a change in the pattern of usage of drugs in Spain, from medicines with a brand name to the so-called generic drugs. In this work we analyze, from the point of view of legal regulation, the application of PPA in Spain, as well as describe the specifics of this practice between the years 2004 and 2014. We observe how the usage of such drugs has increase progressively whilst prescribed drugs have become less and less common. Indeed, generic medication has continued gaining market share through the years, rising from 12% in 2004 to 46,5% in 2014. The availability and use of generic drugs has been especially encouraged through the approval of certain laws and decree-laws, concretely the Decree-law 9/2011, which, sponsored by health authorities with the purpose of decreasing health expenses and 3 ensure the sustainability of the Spanish National Health Service (SNHS), has indirectly caused an increase in the use of generic medicines and drugs without patent protection. At the same time, these measures have reduced considerably the impact on the drug budget of the SNHS from 2010 onwards.
In the last few years there has been a change in the pattern of usage of drugs in Spain, from medicines with a brand name to the so-called generic drugs. In this work we analyze, from the point of view of legal regulation, the application of PPA in Spain, as well as describe the specifics of this practice between the years 2004 and 2014. We observe how the usage of such drugs has increase progressively whilst prescribed drugs have become less and less common. Indeed, generic medication has continued gaining market share through the years, rising from 12% in 2004 to 46,5% in 2014. The availability and use of generic drugs has been especially encouraged through the approval of certain laws and decree-laws, concretely the Decree-law 9/2011, which, sponsored by health authorities with the purpose of decreasing health expenses and 3 ensure the sustainability of the Spanish National Health Service (SNHS), has indirectly caused an increase in the use of generic medicines and drugs without patent protection. At the same time, these measures have reduced considerably the impact on the drug budget of the SNHS from 2010 onwards.